Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways.
METex14
PD-L1
immune checkpoint
pulmonary sarcomatoid sarcoma
signaling pathways
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Jun 2023
27 Jun 2023
Historique:
received:
29
04
2023
revised:
15
06
2023
accepted:
25
06
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Immunotherapy has transformed lung cancer management, but PSC remains an aggressive subtype with a poor prognosis. This study investigates the differential expression of PD-L1 and alternative immune checkpoints (ICs; B7x, B7-H3, and HHLA2), and genetic alterations in PSCs. Tumor specimens of 41 PSC patients were evaluated. PD-L1, B7x, B7-H3, and HHLA2 were positive in 75.0%, 67.6%, 73.0%, and 91.9% of tumors, respectively. PD-L1 expression was significantly higher in the epithelial compared to the sarcomatoid component (median TPS: 50% vs. 0%,
Identifiants
pubmed: 37444481
pii: cancers15133372
doi: 10.3390/cancers15133372
pmc: PMC10340395
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : American Lung Association
ID : LCD-687010
Références
Oncotarget. 2018 Jan 31;9(12):10635-10649
pubmed: 29535832
Clin Lung Cancer. 2022 Dec;23(8):e545-e549
pubmed: 36210290
Clin Lung Cancer. 2018 May;19(3):e323-e333
pubmed: 29454534
N Engl J Med. 2020 Sep 3;383(10):931-943
pubmed: 32469185
Nature. 1987 May 21-27;327(6119):239-42
pubmed: 2952888
Oncotarget. 2015 Feb 20;6(5):3452-61
pubmed: 25609202
Eur J Cardiothorac Surg. 2018 Apr 1;53(4):828-834
pubmed: 29240878
J Clin Oncol. 2016 Mar 1;34(7):721-30
pubmed: 26729443
Immunol Rev. 2017 Mar;276(1):26-39
pubmed: 28258693
Cancer Discov. 2015 Aug;5(8):850-9
pubmed: 25971938
Clin Cancer Res. 2019 Apr 1;25(7):2348-2360
pubmed: 30587547
Nat Immunol. 2003 Sep;4(9):899-906
pubmed: 12925852
Sci Immunol. 2021 Jul 9;6(61):
pubmed: 34244312
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Expert Rev Respir Med. 2016 Apr;10(4):407-416
pubmed: 26962707
J Thorac Oncol. 2017 Jun;12(6):932-942
pubmed: 28315738
Ann Oncol. 2019 Aug 1;30(8):1321-1328
pubmed: 31125062
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9879-84
pubmed: 23716685
J Thorac Oncol. 2020 May;15(5):860-866
pubmed: 31991225
Cell Rep. 2014 Nov 6;9(3):1089-98
pubmed: 25437562
J Clin Oncol. 2016 Mar 10;34(8):794-802
pubmed: 26215952
JTO Clin Res Rep. 2022 Jul 22;3(9):100381
pubmed: 36082279
Clin Lung Cancer. 2019 May;20(3):e242-e246
pubmed: 30665873
N Engl J Med. 2020 Sep 3;383(10):944-957
pubmed: 32877583
Ann Oncol. 2018 Oct 1;29(10):2085-2091
pubmed: 30165371
Eur J Cancer. 2015 Nov;51(17):2698-707
pubmed: 26329973
Clin Lung Cancer. 2020 Sep;21(5):e456-e463
pubmed: 32265109
Trends Pharmacol Sci. 2019 Nov;40(11):883-896
pubmed: 31677920
J Clin Oncol. 2018 Jan 10;36(2):210-216
pubmed: 29220296
Cancer Res. 2022 Apr 1;82(7):1365-1379
pubmed: 35078819
Ann Nucl Med. 2019 Sep;33(9):647-656
pubmed: 31165974
Nat Rev Cancer. 2002 Jun;2(6):442-54
pubmed: 12189386
J Thorac Oncol. 2013 Dec;8(12):1574-7
pubmed: 24389441
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19458-63
pubmed: 18042703
Lung Cancer. 2006 Aug;53(2):143-51
pubmed: 16782226
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Ther Adv Med Oncol. 2020 Aug 25;12:1758835920950207
pubmed: 32922522
Clin Cancer Res. 2018 Apr 15;24(8):1954-1964
pubmed: 29374053
Carcinogenesis. 2010 Apr;31(4):577-86
pubmed: 20097731
Clin Cancer Res. 2017 Feb 1;23(3):825-832
pubmed: 27553831
Lung Cancer. 2016 Aug;98:51-58
pubmed: 27393506
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Sci Adv. 2022 Apr 29;8(17):eabm7012
pubmed: 35476450